RedHill Biopharma Ltd.(RDHL)Earnings, Financials & Key RatiosRedHill Biopharma Ltd. (RDHL) stock price & volume — 10-year historical chart
Investment Thesis • Updated 2025Q2
the company's inability to generate positive free cash flow, coupled with a $418 million accumulated deficit, suggests an imminent risk of further shareholder dilution or insolvency.
RedHill Biopharma Ltd. (RDHL) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Recent stock market news and headlines for RedHill Biopharma Ltd. (RDHL)
$6 million upfront with up to approximately $13.4 million of potential aggregate gross proceeds upon the exercise in full of warrants TEL AVIV, Israel and RALEIGH, N.C., June 22, 2026 /PRNewswire/ -- RedHill Biopharma Ltd.
$6 million upfront with up to approximately $13.4 million of potential aggregate gross proceeds upon the exercise in full of warrants TEL AVIV, Israel & RALEIGH, N.C., June 18, 2026 /PRNewswire/ -- RedHill Biopharma Ltd.
Key metrics vs top competitors for RedHill Biopharma Ltd. (RDHL)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $0.83 | $4.24M | -0.12 | 23.17% | -102.8% | — | — | |
| $2.18 | $301.46M | -5.19 | -100% | — | -39.75% | — | |
| $319.60 | $9.23B | -23.71 | -100% | — | -43.02% | — | |
| $4.12 | $678.21M | 27.47 | -15.72% | 28.26% | — | — | |
| $47.41 | $2.73B | -69.72 | 8.63% | -3.74% | -2.73% | — | |
| $125.17 | $8.05B | -61.06 | -89.41% | -648.27% | -17.76% | — |
RedHill Biopharma Ltd. (RDHL) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Get notified when RDHL posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
RedHill Biopharma Ltd. (RDHL) stock FAQ — growth, dividends, profitability & financials explained
RedHill Biopharma Ltd. (RDHL) reported $9.5M in revenue for fiscal year 2024. This represents a 41422% increase from $0.0M in 2011.
RedHill Biopharma Ltd. (RDHL) grew revenue by 23.2% over the past year. This is strong growth.
RedHill Biopharma Ltd. (RDHL) reported a net loss of $9.3M for fiscal year 2024.
RedHill Biopharma Ltd. (RDHL) had negative free cash flow of $8.2M in fiscal year 2024, likely due to heavy capital investments.
